By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shire Pharmaceuticals Group plc 

Hampshire International Business Park
Basingstoke  Hampshire  RG24 8EP  United Kingdom
Phone: 44-1256-894-000 Fax: 44-1256-894-708



Company News
Shire (SHPGY) Release: FDA Grants Priority Review To Lifitegrast NDA For The Treatment Of Dry Eye Disease In Adults 4/10/2015 10:40:41 AM
Shire (SHPGY) Reports Topline Results From First Of Three Placebo-Controlled Phase 2 Studies Of SHP625 (LUM001) In Children With Alagille Syndrome 4/9/2015 6:52:26 AM
Shire (SHPGY) Announces Clear Regulatory Path Forward For SHP465, An Investigational Treatment For Adults With ADHD 4/7/2015 8:46:30 AM
Shire (SHPGY) Comments On USPTO Petitions Related To LIALDA And GATTEX 4/6/2015 10:02:17 AM
Shire (SHPGY) Release: Natpara (Parathyroid Hormone) For Injection Now Available In The U.S. 4/1/2015 11:08:42 AM
EXCLUSIVE: Shire (SHPGY) Buyout of BioMarin (BMRN) "Seems Obvious," Source Close to the Deal Tells BioSpace (DHX) 3/30/2015 4:23:40 PM
Shire (SHPGY) And Cincinnati Children's Hospital Medical Center's Establish Rare Disease Research Collaboration 3/26/2015 10:15:22 AM
Shire (SHPGY) Will Hand Pink Slips to 600 Employees in Pennsylvania 3/5/2015 6:17:46 AM
Shire (SHPGY) Submits Application To The U.S. D&A Pharma For Approval Of Lifitegrast For Treatment Of Dry Eye Disease In Adults 3/2/2015 7:00:49 AM
Shire (SHPGY) To Present At The Cowen 35th Annual Healthcare Conference 2/25/2015 10:39:25 AM